EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

In this podcast, two oncologists and two patient advocates from the patient advocacy group EGFR Resisters talk about the importance of biomarker testing for patients with non-small cell lung cancer and how this can affect treatment decisions and personalised medicine. The panel discusses what biomarkers are, the processes involved in obtaining biomarker testing, how biomarker information is used, and the importance of waiting for biomarker results prior to determining treatment. The panel also discusses patient perspectives on biopsy and biomarker testing and how healthcare professionals can best help guide new patients through this process.  This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the  Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-023-00242-7. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.   This podcast in intended for medical professionals.